Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome.
Eur Respir Rev
; 29(156)2020 Jun 30.
Article
em En
| MEDLINE
| ID: mdl-32620587
ABSTRACT
Acute respiratory distress syndrome (ARDS) remains a significant source of mortality in critically ill patients. Characterised by acute, widespread alveolar inflammation and pulmonary oedema, its pathophysiological heterogeneity has meant that targeted treatments have remained elusive. Metabolomic analysis has made initial steps in characterising the underlying metabolic derangements of ARDS as an indicator of phenotypical class and has identified mitochondrial dysfunction as a potential therapeutic target. Mesenchymal stem cells and their derived extracellular vesicles have shown significant promise as potential therapies in delivering mitochondria in order to redivert metabolism onto physiological pathways.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome do Desconforto Respiratório
/
Metabolômica
/
Terapia Baseada em Transplante de Células e Tecidos
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article